BioMarin appeases an activist

Off Biotech, biotechnology, Business, cancer, CRISPR, drug development, drug prices, drug pricing, FDA, finance, genetics, government agencies, Health, Human Health, legal, Life Sciences, Medicine, patients, Pharma, Pharmaceuticals, physicians, rare diseases, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with news of an averted activist challenge, biotech on late-night TV, and the latest deal in oncology’s hottest space.

Read the rest…

Read Original Article: BioMarin appeases an activist »

About The Author